411 reports of this reaction
3.4% of all RAMELTEON reports
#3 most reported adverse reaction
SOMNOLENCE is the #3 most commonly reported adverse reaction for RAMELTEON, manufactured by Takeda Pharmaceuticals America, Inc.. There are 411 FDA adverse event reports linking RAMELTEON to SOMNOLENCE. This represents approximately 3.4% of all 11,977 adverse event reports for this drug.
Patients taking RAMELTEON who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among RAMELTEON users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for RAMELTEON:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 411 FDA reports for RAMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 3.4% of all adverse event reports for RAMELTEON, making it one of the most commonly reported side effect.
If you experience somnolence while taking RAMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.